These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 23512167)

  • 21. In vivo characterization of the opioid antagonist nalmefene in mice.
    Osborn MD; Lowery JJ; Skorput AG; Giuvelis D; Bilsky EJ
    Life Sci; 2010 Apr; 86(15-16):624-30. PubMed ID: 20159022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.
    Tsuruda PR; Vickery RG; Long DD; Armstrong SR; Beattie DT
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Jun; 386(6):479-91. PubMed ID: 23549670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties.
    Beattie DT; Armstrong SR; Vickery RG; Tsuruda PR; Campbell CB; Richardson C; McCullough JL; Daniels O; Kersey K; Li YP; Kim KH
    Front Pharmacol; 2011; 2():25. PubMed ID: 21687517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lubiprostone for the treatment of opioid-induced bowel dysfunction.
    Wong BS; Camilleri M
    Expert Opin Pharmacother; 2011 Apr; 12(6):983-90. PubMed ID: 21385112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opioid-induced constipation: challenges and therapeutic opportunities.
    Camilleri M
    Am J Gastroenterol; 2011 May; 106(5):835-42; quiz 843. PubMed ID: 21343919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation.
    Sloots CE; Rykx A; Cools M; Kerstens R; De Pauw M
    Dig Dis Sci; 2010 Oct; 55(10):2912-21. PubMed ID: 20428949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of peripheral opioid antagonists' new insights into opioid effects.
    Moss J; Rosow CE
    Mayo Clin Proc; 2008 Oct; 83(10):1116-30. PubMed ID: 18828971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
    Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R
    Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alvimopan, a selective peripherally acting mu-opioid antagonist.
    Camilleri M
    Neurogastroenterol Motil; 2005 Apr; 17(2):157-65. PubMed ID: 15787936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects.
    Yuan CS
    J Support Oncol; 2004; 2(2):111-7; discussion 119-22. PubMed ID: 15328815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence.
    Kest B; Palmese CA; Hopkins E; Adler M; Juni A; Mogil JS
    Neuroscience; 2002; 115(2):463-9. PubMed ID: 12421612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.
    Schmidt WK
    Am J Surg; 2001 Nov; 182(5A Suppl):27S-38S. PubMed ID: 11755894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of the potential role of methylnaltrexone in opioid bowel dysfunction.
    Foss JF
    Am J Surg; 2001 Nov; 182(5A Suppl):19S-26S. PubMed ID: 11755893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity.
    DeHaven-Hudkins DL; Burgos LC; Cassel JA; Daubert JD; DeHaven RN; Mansson E; Nagasaka H; Yu G; Yaksh T
    J Pharmacol Exp Ther; 1999 Apr; 289(1):494-502. PubMed ID: 10087042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans.
    Murphy DB; Sutton JA; Prescott LF; Murphy MB
    Anesthesiology; 1997 Oct; 87(4):765-70. PubMed ID: 9357876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of morphine and naloxone on behaviour in the hot plate test: an ethopharmacological study in the rat.
    Espejo EF; Stinus L; Cador M; Mir D
    Psychopharmacology (Berl); 1994 Jan; 113(3-4):500-10. PubMed ID: 7862866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 2: in vivo parenteral pharmacology and acute toxicity in mice. Comparison with morphine, codeine and diphenoxylate.
    Niemegeers CJ; Lenaerts FM; Janssen PA
    Arzneimittelforschung; 1974 Oct; 24(10):1636-41. PubMed ID: 4479776
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.